Xeris Biopharma Holdings, Inc. XERS Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 85.9%+3.7pp | 85.4%+3.6pp | 84.6%+3.2pp | 82.2%-1.5pp | 82.2%-0.7pp | |
| Operating margin | 11.4%+22.3pp | 8.5%+25.9pp | 3.1%+27.2pp | -4.7%+15.8pp | -10.9%+15.4pp | |
| Net margin | 3.8%+24.1pp | 0.2%+27.2pp | -5.9%+27.8pp | -13%+19.8pp | -20.3%+17.3pp | |
| Returns | ||||||
| Return on invested capital | 21.4%+34.4pp | 15%+36.8pp | 4.7%+29.1pp | -6.2%+13.1pp | -13%+11.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×+0.2× | 0.8×+0.2× | 0.8×+0.2× | 0.7×+0.2× | 0.7×+0.2× | |
| Liquidity | ||||||
| Current ratio | 2.1×+0.4× | 2.2×+0.5× | 1.9×+0.1× | 1.9×-0.3× | 1.7×-0.7× | |
| Per Share | ||||||
| Book value per share | $0.07+132% | $0.08+139% | -$0.00+97.5% | -$0.12+6.8% | -$0.23-253% | |
| Valuation | ||||||
| Market capitalization | $1.28B+76.9% | $1.3B+158% | $1.31B+211% | $746.32M+136% | $845.13M+178% | |
| Price / sales | 4.1×+0.8× | 4.5×+2.0× | 4.9×+2.7× | 3×+1.3× | 3.8×+2.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Xeris Biopharma Holdings, Inc. (XERS) runs a 85.9% gross margin and a 11.4% operating margin, with a 3.8% net margin.
- Where do Xeris Biopharma Holdings, Inc.'s ratios come from?
- Every ratio is computed from Xeris Biopharma Holdings, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
